• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Heterozygous (PubMed=18505964).
  

PubMed=7747814; PMCID=PMC1869278
Gruis N.A., Weaver-Feldhaus J.M., Liu Q.-Y., Frye C., Eeles R., Orlow I., Lacombe L., Ponce-Castaneda V., Lianes P., Latres E., Skolnick M.H., Cordon-Cardo C., Kamb A.
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression.
Am. J. Pathol. 146:1199-1206(1995)

PubMed=18505964; DOI=10.1093/jnci/djn157; PMCID=PMC4410798
Freedberg D.E., Rigas S.H., Russak J.E., Gai W.-M., Kaplow M.E., Osman I., Turner F., Randerson-Moor J.A., Houghton A.N., Busam K.J., Bishop D.T., Bastian B.C., Newton-Bishop J.A., Polsky D.
Frequent p16-independent inactivation of p14ARF in human melanoma.
J. Natl. Cancer Inst. 100:784-795(2008)

PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958; PMCID=PMC3070783
Rose A.E., Poliseno L., Wang J.-H., Clark M., Pearlman A., Wang G.-M., Vega y Saenz de Miera E.C., Medicherla R., Christos P.J., Shapiro R., Pavlick A., Darvishian F., Zavadil J., Polsky D., Hernando E., Ostrer H., Osman I.
Integrative genomics identifies molecular alterations that challenge the linear model of melanoma progression.
Cancer Res. 71:2561-2571(2011)